These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37890702)

  • 1. Cost and utilization of healthcare services for persons with diabetes.
    Reynolds EL; Mizokami-Stout K; Putnam NM; Banerjee M; Albright D; Ang L; Lee J; Pop-Busui R; Feldman EL; Callaghan BC
    Diabetes Res Clin Pract; 2023 Nov; 205():110983. PubMed ID: 37890702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United States.
    Joish VN; Zhou FL; Preblick R; Lin D; Deshpande M; Verma S; Davies MJ; Paranjape S; Pettus J
    J Manag Care Spec Pharm; 2020 Mar; 26(3):311-318. PubMed ID: 32105172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Out-of-Pocket Costs for Type 2 Diabetes Medications When Aging Into Medicare.
    Barthold D; Li J; Basu A
    JAMA Netw Open; 2024 Jul; 7(7):e2420724. PubMed ID: 38980673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of type 2 diabetes medication cost sharing on patient outcomes and health plan costs.
    Thornton Snider J; Seabury S; Lopez J; McKenzie S; Goldman DP
    Am J Manag Care; 2016 Jun; 22(6):433-40. PubMed ID: 27355811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of patient out-of-pocket costs for insulin on medication adherence and health care utilization in patients with commercial insurance; 2007-2018.
    McAdam-Marx C; Ruiz-Negron N; Sullivan JM; Tucker JM
    J Manag Care Spec Pharm; 2022 May; 28(5):494-506. PubMed ID: 35392659
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease.
    King A; Rajpura J; Liang Y; Paprocki Y; Uzoigwe C
    Curr Med Res Opin; 2022 Nov; 38(11):1831-1840. PubMed ID: 36134459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changing costs of type 1 diabetes care among US children and adolescents.
    Crossen S; Xing G; Hoch JS
    Pediatr Diabetes; 2020 Jun; 21(4):644-648. PubMed ID: 32061049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States.
    Simeone JC; Shah S; Ganz ML; Sullivan S; Koralova A; LeGrand J; Bushman J
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1399-1410. PubMed ID: 33119443
    [No Abstract]   [Full Text] [Related]  

  • 9. Health Care Utilization and Costs of Publicly-Insured Children with Diabetes in California.
    Lee JM; Sundaram V; Sanders L; Chamberlain L; Wise P
    J Pediatr; 2015 Aug; 167(2):449-54.e6. PubMed ID: 26028286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare costs among adults with type 2 diabetes initiating saxagliptin or linagliptin: a US-based claims analysis.
    Kong AM; Farahbakhshian S; Pendergraft T; Brouillette MA; Mukherjee B; Smith DM; Sheehan JJ
    Curr Med Res Opin; 2017 Oct; 33(10):1869-1877. PubMed ID: 28613952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes Care Barriers, Use, and Health Outcomes in Younger Adults With Type 1 and Type 2 Diabetes.
    Pihoker C; Braffett BH; Songer TJ; Herman WH; Tung M; Kuo S; Bellatorre A; Isganaitis E; Jensen ET; Divers J; Zhang P; Nathan DM; Drews K; Dabelea D; Zeitler PS;
    JAMA Netw Open; 2023 May; 6(5):e2312147. PubMed ID: 37145592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
    Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
    J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in Diabetes-Related Hospitalizations and Medical Costs After Dexcom G6 Continuous Glucose Monitor Initiation in People with Type 2 Diabetes Using Intensive Insulin Therapy.
    Hannah KL; Nemlekar PM; Green CR; Norman GJ
    Adv Ther; 2024 Jun; 41(6):2299-2306. PubMed ID: 38619722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
    Jendle J; Ericsson Å; Ekman B; Sjöberg S; Gundgaard J; da Rocha Fernandes J; Mårdby AC; Hunt B; Malkin SJP; Thunander M
    J Med Econ; 2020 Nov; 23(11):1311-1320. PubMed ID: 32746676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Out-of-Pocket Annual Health Expenditures and Financial Toxicity From Healthcare Costs in Patients With Heart Failure in the United States.
    Wang SY; Valero-Elizondo J; Ali HJ; Pandey A; Cainzos-Achirica M; Krumholz HM; Nasir K; Khera R
    J Am Heart Assoc; 2021 Jul; 10(14):e022164. PubMed ID: 33998273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus.
    Guo JJ; Gibson JT; Gropper DM; Oswald SL; Barker KN
    Am J Manag Care; 1998 Oct; 4(10):1433-46. PubMed ID: 10338736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Out-of-pocket expenses and healthcare resource utilization among individuals with or at risk of diabetes mellitus.
    Fox KM; Grandy S;
    Curr Med Res Opin; 2008 Dec; 24(12):3323-9. PubMed ID: 18954500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated Costs and Healthcare Resource Utilization in Patients With Type 2 Diabetes and Established Cardiovascular Disease in Israel.
    Melzer Cohen C; Hallén N; Chodick G; Bourvine L; Waner T; Karasik A
    Value Health Reg Issues; 2020 Sep; 22():83-92. PubMed ID: 32798839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States.
    McGarvey N; Gitlin M; Fadli E; Chung KC
    J Med Econ; 2023; 26(1):1318-1329. PubMed ID: 37907436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin.
    Parker ED; Wittbrodt ET; McPheeters JT; Frias JP
    Diabetes Obes Metab; 2019 Feb; 21(2):227-233. PubMed ID: 30101553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.